Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exact Sciences Cor (NQ: EXAS )

69.30 -1.16 (-1.65%)
Streaming Delayed Price Updated: 10:53 AM EDT, Oct 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Exact Sciences Cor

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Will EXACT SCIENCES CORP breakout?
With a solid technical rating of 8 out of 10, EXACT SCIENCES CORP (NASDAQ:EXAS) is showing strong indications of a possible breakout. 
Via Chartmill
Deep Dive Into Exact Sciences Stock: Analyst Perspectives (7 Ratings)
Via Benzinga
Can This Beaten-Down Cathie Wood Stock Bounce Back?
An updated version of Exact Sciences' key product just got regulatory approval. That could help the healthcare stock stage a comeback. 
Via The Motley Fool
(EXAS) - Analyzing Exact Sciences's Short Interest
Via Benzinga
FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test
Exact Sciences' Cologuard Plus test, now FDA-approved, offers a non-invasive screening option for adults 45+ at average risk for colorectal cancer. The test outperformed fecal immunochemical tests in... 
Via Benzinga
Exposures Product Safety
Exact Sciences Stock Rises After FDA Signs Off On New Cologuard
The company is soon to launch its next-generation colon cancer screening tool. 
Via Investor's Business Daily
Exposures Product Safety
Analyst Ratings For Exact Sciences
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Exact Sciences
Via Benzinga
Exact Sciences Analysts Slash Their Forecasts After Q2 Results
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Chewy, Broadcom And MicroStrategy Are Among Top 10 Large Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?
These ten stocks saw significant gains last week, with Summit Therapeutics up 98.32% and BioNTech up 31.77%. Analysts also raised price targets for Applovin and Arm Holdings. 
Via Benzinga
Exact Sciences To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Sector Spotlight: Top 4 Basket of Diagnostic Stocks (EXAS, GH, ILMN, LUDG)
Sector Spotlight: Top 4 Basket of Diagnostic Stocks (EXAS, GH, ILMN, LUDG) 
Via News Direct
Exposures COVID-19
Peeling Back The Layers: Exploring Exact Sciences Through Analyst Insights
Via Benzinga
Expert Outlook: Exact Sciences Through The Eyes Of 5 Analysts
Via Benzinga
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
DoorDash And Exact Sciences Are Among Top 10 Large Cap Gainers Last Week (July 28-Aug 3): Are The Others In Your Portfolio?
Top 10 stocks with highest gains last week, including Exact Sciences, Alnylam Pharmaceuticals, Resmed, Coca-Cola Consolidated, DexCom, Sprouts Farmers Market, UL Solutions, Labcorp Holdings, C.H.... 
Via Benzinga
Crude Oil Moves Lower; Moderna Shares Plunge
Via Benzinga
Exposures Fossil Fuels
Dow Dips Over 500 Points; ISM Manufacturing PMI Falls In July
Via Benzinga
Topics Stocks
Exposures US Equities
Air Products Posts Upbeat Earnings, Joins Meta, Exact Sciences, Shake Shack, Clearwater Analytics And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Why Exact Sciences, Up 20%, Is 'Coiled To Snap Back' After Quarterly Beat
The company expects stronger second-half sales vs. the first half of 2024. 
Via Investor's Business Daily
Exact Sciences (EXAS) Q2 2024 Earnings Call Transcript
EXAS earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Exact Sciences Stock Climbs After Strong Q2 Results
Exact Sciences shares are trading higher after the company reported its second-quarter financial results Wednesday. Here's a look at the details from the report: 
Via Benzinga
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The strugglingh stock investor did a little bit of shopping on Tuesday, adding to some of her existing positions. 
Via The Motley Fool
FDA Greenlights Guardant Health's Shield Blood Test, Analyst Cautious on Adoption
FDA approves Guardant Health's Shield blood test for colorectal cancer screening in adults 45+, marking the first FDA-approved blood test as a primary CRC screening option. Shield meets Medicare... 
Via Benzinga
Exposures Product Safety
Goldman Sachs Says Buy These 3 Stocks for Double-Digit Returns
The investment banking firm says these companies are among the best stocks to buy and have some strong tailwinds behind them. 
Via InvestorPlace
This Cathie Wood Growth Stock Could Soar by 93%, According to Wall Street
Investors shouldn't rush to buy the stock based on rosy short-term price targets. 
Via The Motley Fool
The 3 Best Personalized Medicine Stocks to Buy in July 2024
Explore promising personalized medicine stocks poised for growth as the industry expands, driven by advancements in genomic technologies. 
Via InvestorPlace
NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Mainz Biomed’s ColoAlert Potentially Puts It On A Similar Track As Big Name Cancer Screening Stocks
Mainz Biomed’s ColoAlert Potentially Puts It On A Similar Track As Big Name Cancer Screening Stocks 
Via News Direct
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.